Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has been awarded a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This funding will support the integration of hematocrit measurement into a future generation Blood Volume Analyzer (BVA).
The upgrade aims to streamline the BVA test by eliminating the need for third-party hematocrit testing devices. This marks Daxor's eighth SBIR award, demonstrating the DHA's ongoing commitment to advancing next-generation medical technologies. The company's goal is to make blood volume measurement faster and easier in various settings, from bedside to clinical testing labs and combat zones.
Daxor (Nasdaq: DXR), il leader globale nella tecnologia di misurazione del volume sanguigno, ha ricevuto un finanziamento abbinato di $550K dalla U.S. Defense Health Agency (DHA) per il suo contratto Phase II SBIR. Questo finanziamento sosterrà l'integrazione della misurazione dell'ematocrito in una futura generazione di Blood Volume Analyzer (BVA).
L'aggiornamento mira a semplificare il test BVA eliminando la necessità di dispositivi di test dell'ematocrito di terze parti. Questo rappresenta il ottavo premio SBIR di Daxor, dimostrando l'impegno continuo della DHA verso l'avanzamento delle tecnologie mediche di nuova generazione. L'obiettivo dell'azienda è rendere la misurazione del volume sanguigno più veloce e semplice in vari contesti, dagli ospedali ai laboratori di analisi cliniche e zone di combattimento.
Daxor (Nasdaq: DXR), el líder mundial en tecnología de medición del volumen sanguíneo, ha recibido una extensión de fondos coincidentes de $550,000 de la Agencia de Salud de Defensa de EE. UU. (DHA) para su contrato SBIR de Fase II. Este financiamiento apoyará la integración de la medición del hematocrito en una futura generación de Blood Volume Analyzer (BVA).
La actualización tiene como objetivo simplificar la prueba BVA al eliminar la necesidad de dispositivos de prueba de hematocrito de terceros. Este es el octavo premio SBIR de Daxor, lo que demuestra el compromiso continuo de la DHA para avanzar en tecnologías médicas de próxima generación. El objetivo de la empresa es hacer que la medición del volumen sanguíneo sea más rápida y fácil en diversos entornos, desde la cama del paciente hasta laboratorios de pruebas clínicas y zonas de combate.
Daxor (Nasdaq: DXR)는 혈액량 측정 기술의 글로벌 리더로서, 미국 방위 건강국(DHA)으로부터 55만 달러의 매칭 기금 연장을 받았습니다. 이 자금은 차세대 혈액량 분석기(BVA)에 헤마토크릿 측정을 통합하는 데 지원될 것입니다.
이번 업그레이드는 제3자 헤마토크릿 측정 장비의 필요성을 제거하여 BVA 테스트를 간소화하는 것을 목표로 하고 있습니다. 이는 Daxor의 여덟 번째 SBIR 수상으로, DHA의 차세대 의료 기술 발전에 대한 지속적인 의지를 보여줍니다. 회사의 목표는 침상에서 임상 테스트 실험실 및 전투 지역에 이르기까지 다양한 환경에서 혈액량 측정을 빠르고 쉽게 만드는 것입니다.
Daxor (Nasdaq: DXR), leader mondial dans la technologie de mesure du volume sanguin, a reçu une extension de fonds de correspondance de 550 000 $ de la Defense Health Agency (DHA) des États-Unis pour son contrat SBIR Phase II. Ce financement soutiendra l'intégration de la mesure de l'hématocrite dans une future génération de Blood Volume Analyzer (BVA).
La mise à niveau vise à simplifier le test BVA en éliminant le besoin d'appareils de test d'hématocrite tiers. Cela marque la huitième récompense SBIR de Daxor, démontrant l'engagement continu de la DHA à faire avancer les technologies médicales de nouvelle génération. L'objectif de l'entreprise est de rendre la mesure du volume sanguin plus rapide et plus facile dans divers contextes, allant des lits de patients aux laboratoires d'analyses cliniques et aux zones de combat.
Daxor (Nasdaq: DXR), der globale Marktführer in der Technologie zur Messung des Blutvolumens, hat von der U.S. Defense Health Agency (DHA) eine Erweiterung der Matching-Finanzierung in Höhe von 550.000 $ für seinen Phase II SBIR-Vertrag erhalten. Diese Finanzierung wird die Integration der Hämatokritmessung in eine zukünftige Generation des Blood Volume Analyzers (BVA) unterstützen.
Das Upgrade zielt darauf ab, den BVA-Test zu optimieren, indem die Notwendigkeit für Drittanbieter-Geräte zur Hämatokritmessung entfällt. Dies ist die achte SBIR-Auszeichnung von Daxor und zeigt das anhaltende Engagement der DHA zur Weiterentwicklung medizinischer Technologien der nächsten Generation. Das Ziel des Unternehmens ist es, die Blutvolumenmessung in verschiedenen Umgebungen, von der Patientenversorgung bis hin zu klinischen Testlabors und Kampfgebieten, schneller und einfacher zu gestalten.
- Received $550K matching-fund extension from U.S. Defense Health Agency
- Eighth SBIR award, indicating consistent government support
- Development of advanced blood volume measurement technology
- Potential for improved adoption of next-generation analyzer
- None.
Insights
The award of the additional $550K matching-fund extension from the U.S. Defense Health Agency (DHA) is a positive financial development for Daxor Corporation. This funding extension indicates strong government backing, which can be a significant driver of future revenue growth. Additionally, the integration of hematocrit measurement into the blood volume analyzer could reduce operational costs by eliminating the need for third-party devices. This move may enhance Daxor’s market position, potentially leading to increased sales and market penetration. Investors should consider this as a sign of confidence in Daxor’s technology and its future profitability.
The integration of hematocrit measurement into Daxor’s next-generation blood volume analyzer is a critical advancement in medical technology. Hematocrit levels are a key parameter in diagnosing and monitoring various medical conditions, including anemia and polycythemia. By providing a more streamlined and efficient process, Daxor's new analyzer can significantly benefit clinicians and patients by offering quicker and more reliable results. This innovation could set a new standard in blood volume analysis, improving patient outcomes and driving adoption in clinical settings.
Daxor’s receipt of its eighth SBIR award is indicative of the company's strong track record in securing government contracts, which can be a reliable revenue stream. The U.S. Defense Health Agency's support not only enhances Daxor’s credibility but also helps in accelerating the development of their technology. The integration of hematocrit measurement into a single device may differentiate Daxor in a competitive market, potentially leading to a larger market share. This development could also open doors to additional contracts and partnerships, further solidifying Daxor’s position in the medical technology industry.
The Hematocrit Feature Will Be Integrated Into A Future Generation Blood Volume Analyzer (BVA)
Oak Ridge, TN, July 24, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that Daxor has received a
“The DHA's continued support demonstrates their ongoing commitment to advancing next-generation medical technologies like Daxor’s BVA," said Michael Feldschuh, CEO and President of Daxor Corporation. “The addition of built-in hematocrit measurement will streamline our next-generation analyzer's adoption. We aim to make blood volume measurement faster and easier in all settings, from the bedside to clinical testing labs to combat zones.”
“This represents our eighth SBIR award to support the continued development of our next generation technologies,” commented Jonathan Feldschuh, Daxor’s Chief Science Officer. “We have an ongoing commitment to working with government funders to effectively and efficiently develop the most advanced technology for blood volume measurement and its clinical application.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the value of the contract extension Daxor (DXR) received from the U.S. Defense Health Agency?
What new feature will be integrated into Daxor's (DXR) future generation Blood Volume Analyzer?
How many SBIR awards has Daxor (DXR) received to date?
What is the main benefit of adding hematocrit measurement to Daxor's (DXR) Blood Volume Analyzer?
